Your browser doesn't support javascript.
loading
Risk of hospitalized depression and intentional self-harm with brand and authorized generic sertraline.
Pennap, Dinci D; Swain, Richard S; Welch, Emily C; Bohn, Justin; Lyons, Jennifer G; Dutcher, Sarah; Mosholder, Andrew D.
Afiliación
  • Pennap DD; U.S. Food and Drug Administration Center for Drug Evaluation and Research, Division of Epidemiology I, Silver Spring MD, United States. Electronic address: dinci.pennap@fda.hhs.gov.
  • Swain RS; U.S. Food and Drug Administration Center for Drug Evaluation and Research, Division of Epidemiology I, Silver Spring MD, United States.
  • Welch EC; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston MA, United States.
  • Bohn J; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston MA, United States.
  • Lyons JG; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston MA, United States.
  • Dutcher S; U.S. Food and Drug Administration Center for Drug Evaluation and Research, Regulatory Science Staff, Silver Spring MD, United States.
  • Mosholder AD; U.S. Food and Drug Administration Center for Drug Evaluation and Research, Division of Epidemiology I, Silver Spring MD, United States.
J Affect Disord ; 296: 635-641, 2022 01 01.
Article en En | MEDLINE | ID: mdl-34619154

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Conducta Autodestructiva / Sertralina Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Affect Disord Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Conducta Autodestructiva / Sertralina Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Affect Disord Año: 2022 Tipo del documento: Article